Anthocyanins from black wolfberry (*Lycium ruthenicum* Murr.) prevent inflammation and increase fecal fatty acid in diet-induced obese rats†

Jinjin Yinab and Tao Wua,*

This study aimed to determine whether black wolfberry (*Lycium ruthenicum* Murr.) anthocyanin (BWA) consumption can alleviate oxidative stress and reduce inflammation in high-fat diet-induced obese male Sprague-Dawley rats. In the present study, BWA at doses of 50, 100, and 200 mg kg⁻¹ were supplemented in the daily food of obese rats during an eight-week experiment. Consumption of BWA at doses of 50, 100, and 200 mg kg⁻¹ reduced bodyweight gain by 17.4%, 18.7 and 38.3%, respectively, in HFD-fed SD rats. BWA could effectively decrease Lee’s index, improve the biochemical profiles, elevate superoxide dismutase activities and fecal fatty acid content, but significantly reduce malondialdehyde (MDA) production and down-regulate the expression of the TNFα, IL-6, NF-κB, IFN-γ and iNOS genes. Therefore, BWA potentially prevents diet-induced obesity by alleviating oxidative stress, reducing inflammation and accelerating fat decomposition in diet-induced obesity.

1. Introduction

Obesity and its associated metabolic disorders, including coronary heart disease, type II diabetes mellitus, reproductive and gastrointestinal cancers, have become global diseases that carry considerable morbidity and mortality.1–3 Obesity results from a prolonged energy imbalance, which is influenced by unhealthy eating habits, mood, and environmental as well as genetic factors.4 The currently available drugs for obesity exhibit adverse effects and high rates of secondary failure.5–7 Therefore, food ingredients with anti-obesity effects need to be developed.

Anthocyanin belongs to the widespread flavonoid group of polyphenols, which are commonly found in our daily diets, especially in berry fruits. In recent years, many animal studies have suggested that anthocyanin can decrease body weight, and reduce the risk for diabetes and cardiovascular diseases. Anthocyanin from black rice (*Oryza sativa* L.),8 black soybean (*Glycine max* L.),9,10 purple corn (*Zea mays* L.),11–12 purple sweet potato (*Ipomoea batatas* L.),13,14 blueberry (*Vaccinium angustifolium*),15,16 or mulberry (*Morus australis* Poir)17,18 prevented bodyweight gain and metabolic aberrations in the diet-induced obese animal models. In spite of the numerous published studies, the underlying fundamental mechanisms are still not fully understood.

Black wolfberry (*Lycium ruthenicum* Murr.) is a unique nutritional food because of the human health benefits, which widely distributes in the northwest of China.19–20 The ripe black wolfberries are rich in anthocyanins. To the best of our knowledge, the effects of black wolfberry anthocyanin (BWA) on weight loss have not been reported. Therefore, the present study aimed to investigate whether BWA alter bodyweight by alleviating oxidative stress and inflammation in diet-induced obesity.

2. Materials and methods

2.1 Materials

Black wolfberry was obtained from the agricultural logistics center in Qinghai. BWA was purified according to the process described by Wu et al.21 BWA is composed of petunidin-3-rutinoside-5-glucosides (78.6%), petunidin-3-glucoside-5-glucoside (8.7%), and delphinidin-3-rutinoside-5-glucoside (12.7%). All other chemicals were of reagent grade.

2.2 Experimental animals and supplement

All the experimental procedures were approved by the Committee on the Ethics of Animal Experiments of Tianjin University of Science & Technology (TUST20160202) and according to the National Institutes of Health Guide for Care and Use of Laboratory Animals. Sixty male Sprague-Dawley (SD) rats (SPF grade, body weight ~ 130 g) were purchased from the Beijing Laboratory Animal Center of the Academy of Military Medical Sciences, and maintained in a room with an alternating
12 h/12 h light/dark cycle at 23 ± 3 °C, and provided free access to water and food.

After 7 days acclimation, the rats were divided in two groups including normal control group (NC, 12 rats) fed low fat diet (LFD) and high fat diet group (48 rats) based on a randomized block design. Rats in the HFD group were supplied with a HFD for 2 weeks to induce obesity, and then divided into 4 subgroups (12 rats): a control group provided with distilled water (MC), a group fed with HFD added with BWA at 50 mg kg⁻¹, a group fed with HFD added with BWA at 100 mg kg⁻¹, and a group fed with HFD added with BWA at 200 mg kg⁻¹, respectively, for another 8 week experiment. During the experimental periods, no rat died and no untoward effects were observed. At the end of experiment, all rats were anesthetized with ketamine-HCl following a 12 h fast and then sacrificed by decapitation. Samples of serum, liver and adipose tissues were immediately collected and stored at −80 °C until the analytical procedures were carried out.

2.3 Serum parameter analyses
The rat serum parameters, including triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc), malondialdehyde (MDA) levels, and superoxide dismutase (SOD) activities, were determined using commercially available kits (BioSino, China) in accordance with the manufacturer’s instructions.

2.4 Hepatic biochemical analysis
Rat liver samples were homogenized in PBS, and lipids were subsequently determined using Folch et al. method. The concentrations of hepatic TG, TC, MDA levels and SOD activities were estimated using the same kit for serum analysis.

2.5 Fecal fatty acid analysis
The feces samples grinded and treated with chloroform–methanol (2 : 1, V/V), and then derived by sulfuric acid–methanol.
methyl esterification. The fatty acid composition and concentration of rat feces were analyzed according to Ahrens et al. method.\(^{23}\)

### 2.6 Quantitative real-time PCR

The total RNA from the rat liver samples was extracted by trizol (Invitrogen Technologies, USA) according to the manufacturer’s instruction. Then they were reverse transcribed into cDNA, and the expression of tumor necrosis factor \(\alpha\) (TNF-\(\alpha\)), interleukin-6 (IL-6), interferon gamma (IFN-\(\gamma\)), nuclear factor \(\kappa B\) (NF-\(\kappa B\)), and inducible nitric oxide synthase (iNOS) genes were examined by PCR (Bio-Rad) using the One Step SYBR Prime Script PLUS RT-PCR kit (TaKaRa, Japan).

### 2.7 Statistical analysis

All experimental data were expressed as mean \(\pm\) standard deviation (SD). The significance of treatment effects was analyzed using Duncan’s multiple range tests after SPSS one-way ANOVA (SPSS PASW Statistic 19.0, SPSS Inc. Chicago, IL, USA). \(p < 0.05\) was considered significant.

### 3. Results

#### 3.1 Effects of BWA on the bodyweight gain of rats

When the rat fed with HFD were administered with BWA at 50 mg kg\(^{-1}\), 100 mg kg\(^{-1}\), 200 mg kg\(^{-1}\) for eight weeks, the body weight gain was effectively reduced by 17.4%, 18.7 and 38.3%, respectively, compared with MC group. No significant difference in the daily food intake was indicated among the HFD-fed group throughout the experimental period. However, BWA significantly decrease food utilization, and effectively low Lee’s index compared with the MC group (Fig. 1). These data may suggest that the weight-reducing effects by BWA was not caused by appetite suppression, but rather attributed to decreasing food efficiency.\(^{24}\) In addition, the weights of the heart and kidney of the rat remained constant after the experiment. However, the liver and fat indexes of rat in the MC groups were higher than that of NC groups, feeding with BWA significantly improved these symptoms.

#### 3.2 Effects of BWA on serum parameters

Fig. 2 suggested that BWA at high dose effectively attenuated the serum TC and LDLC levels and significantly increased the concentration of HDLC levels and SOD activities relative to those in the MC group. Intake of BWA at middle dose remarkably elevated the HDLC levels and SOD activities, but did not alter the TC and LDLC levels. Furthermore, we found an interesting phenomenon that BWA at low dose notably decreased serum MDA levels than the other dose, which is contrary to the previous experiment. The reason for such differences remain unclear, they may be attributed to the composition and structure variations.\(^{25-27}\)

#### 3.3 Effects of BWA on hepatic lipids and antioxidants

Fig. 3 showed the increased hepatic lipids of the rat fed with HFD relative to those fed with LFD; however, BWA consumption could decrease HFD-induced hepatic lipids. By contrast, BWA at high dose significantly decreased lipid TG and TC levels in the HFD-fed rat, but BWA at middle dose only decreased the TC levels. Moreover, SOD activities in the liver of rat in the BWA groups markedly increased relative to those in the MC groups. MDA levels, as an indicator of lipid peroxidation, were significantly higher in the MC group than those in the NC controls. However, MDA levels significantly decreased in the BWA treatment groups.

#### 3.4 Effects of BWA on fecal lipids

Fig. 4 suggested that the rat feces contained four types of long-chain fatty acids including palmitic acid, stearic acid, oleic acid and linoleic acid. The least amounts of these fatty acids were
found in NC, followed by MC. The fecal lipid contents in the BWA groups were significantly higher than those in the MC group, which indicated BWA could inhibit the absorption of lipids in the gut.

3.5 Effects of BWA on inflammation

Fig. 5 showed that rat fed with HFD significantly increased the TNFα, IL-6, IFN-γ, iNOS, and NF-κB genes compared with those fed with LFD. BWA supplementation remarkably down-regulated expression levels of TNFα, IL-6, NF-κB, IFN-γ and iNOS genes compared with the MC group.

4. Discussion

Many studies have shown that fruit anthocyanin may contribute to reducing the risk of cardiovascular disease and can exert a variety of other human beneficial effects.27–31 However, studies on the specific mechanisms of how BWA exert anti-obesity have not been fully conducted. In the present study, we investigated whether BWA alter bodyweight by alleviating oxidative stress and inflammation in diet-induced obese male Sprague-Dawley rats.

Diets with relatively high-fat content long-term can induce overweight and adiposity in humans and animals.32,33 The SD rats fed with an HFD exhibited a significant bodyweight gain, higher Lee’s index, an elevation of lipid profiles, a marked up-regulation of the expression of inflammatory cytokine levels, increased lipid deposition, a reduction in SOD activities. There might be dose-dependent effects of anthocyanin consumption on body weight gain.34–36 Supplementation with BWA at 200 mg kg⁻¹ effectively attenuated body weight gain, markedly elevated the serum HDLC levels and total SOD activities, increased the fecal lipid contents, significantly decreased the hepatic lipids and MDA levels, markedly down-regulated expression levels of TNFα, IL-6, NF-κB, IFN-γ and iNOS genes.

Consistently, our current study demonstrated that BWA significantly decrease food utilization, and markedly increased the fecal lipid contents. This phenomenon suggests BWA may prevent bodyweight gain by inhibiting lipids absorption and accelerate fat decomposition in diet-induced obesity.

Epidemiological studies demonstrated that HFD-induced obesity and associated hepatic fat accumulation could increase oxidative stress, which increased MDA levels and decreased antioxidant enzyme activities.28,35,36 Numerous studies have documented the beneficial effects of polyphenols against oxidative stresses.27–28 In the present study, antioxidant properties in liver were significantly enhanced by BWA.
mediate in kappa B (NF-$\kappa$B) translocation to the nucleus cellular and the lipopolysaccharides (LPS)-induced nuclear factor-
whereby anthocyanins exert anti-obesity e
signi
ficacy, host’s metabolism.

endotoxemia and reduce the impact of a high-fat diet on the diet-induced obesity.

BWA can alter bodyweight by alleviating oxidative stress, levels of TNF-$\alpha$, IL-6, NF-$\kappa$B, IFN-$\gamma$ and iNOS genes, marked down-regulated expression levels of anti-inflammatory cytokines, which elevate the inflammatory cytokine levels, such as TNF-$\alpha$, IL-6, NF-$\kappa$B, IFN-$\gamma$ and iNOS genes, whereas BWA treatment significantly improved the inflammation. The mechanisms whereby anthocyanins exert anti-obesity effects are still not clear. Possible mechanisms suggested have included: attenuation the lipopolysaccharides (LPS)-induced nuclear factor-kappa B (NF-$\kappa$B) translocation to the nucleus cellular and mediate inflammatory responses, reduction in food efficiency, inhibitory effects on adipogenesis, normalize the ratio between beneficial and pathogenic bacteria and plasma endotoxemia and reduce the impact of a high-fat diet on the host’s metabolism.

5. Conclusions

In conclusion, our results showed that supplementation with BWA at 200 mg kg$^{-1}$ effectively attenuated body weight gain, markedly elevated the serum HDLC and T-SOD levels, increased the fecal fatty acid excretion, significantly decreased the hepatic lipids and MDA levels, marked down-regulated expression levels of TNF-$\alpha$, IL-6, NF-$\kappa$B, IFN-$\gamma$ and iNOS genes. Therefore, BWA can alter bodyweight by alleviating oxidative stress, reducing inflammation and accelerating fat decomposition in diet-induced obesity.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is supported by the National Natural Science Foundation of China (31501475), the Youth Innovation Fund of Tianjin University of Science and Technology (2016LG16), Tianjin Natural Science Foundation (15JCQNJC46300), Tianjin Fundamental Research Funds for the Universities (2017KDZD02) and SKLCBSC-2014011.

References

1 S. Yoshimoto, T. M. Loo, K. Atarashi, H. Kanda, S. Sato, S. Oyadomari, Y. Iwakura, K. Oshima, H. Morita, M. Hattori, K. Honda, Y. Ishikawa, E. Hara and N. Ohtani, Nature, 2013, 499, 97–101.
2 P. G. Kopelman, Nature, 2000, 404, 635–643.
3 K. Aleksandrova, M. Stelmach-Mardas and S. Schlesinger, in Obesity and Cancer, Springer, 2016, pp. 177–198.
4 A. R. Saltiel, Sci. Transl. Med., 2016, 8, 323.
5 K. Casazza, K. R. Fontaine, A. Astrup, L. L. Birch, A. W. Brown, M. M. Bohan Brown, N. Durant, G. Dutton, E. M. Foster, S. B. Heymsfield, K. McIver, T. Mehta, N. Menachemi, P. K. Newby, R. Pate, B. J. Rolls, B. Sen, D. L. Smith Jr, D. M. Thomas and D. B. Allison, N. Engl. J. Med., 2013, 368, 446–454.
6 E. E. Laddenheim, Drug Des., Dev. Ther., 2015, 9, 1867–1875.
7 K. H. Kim and Y. Park, Annu. Rev. Food Sci. Technol., 2011, 2, 237–257.
8 S. L. Yao, Y. Xu, Y. Y. Zhang and Y. H. Lu, Food Funct., 2013, 4, 1602–1608.
9 S. H. Kwon, I. S. Ahn, S. O. Kim, C. S. Hong, H. Y. Chung, M. S. Do and K. Y. Park, J. Med. Food, 2007, 10, 552–556.
10 H. K. Kim, J. N. Kim, S. N. Han, J. H. Nam, H. N. Na and T. J. Ha, Nutr. Res., 2012, 32, 770–777.
11 T. Tsuda, F. Horio, K. Uchida, H. Aoki and T. Osawa, J. Nutr., 2003, 133, 2125–2130.
12 T. Wu, X. Guo, M. Zhang, L. Yang, R. Liu and J. Yin, Food Funct., 2017, 8, 3178–3186.
13 S. J. Shi, U. J. Bae, S. O. Ka, S. J. Woo, S. O. Noh, Y. S. Kwon, K. H. Jung, J. H. Wee and B. H. Park, Int. J. Pharm., 2013, 9, 42–49.
14 Y. P. Hwang, J. H. Choi, E. H. Han, H. G. Kim, J. H. Wee, K. O. Jung, K. H. Jung, K. I. Kwon, T. C. Jeong, Y. C. Chung and H. G. Jeong, Nutr. Res., 2011, 31, 896–906.
15 I. C. Lee, D. Y. Kim and B. Y. Choi, J. Cancer Prev., 2014, 19, 209–215.
16 T. Wu, Z. Jiang, J. Yin, H. Long and X. Zheng, Int. J. Food Sci. Nutr., 2016, 67, 257–264.
17 J. J. Chang, M. J. Hsu, H. P. Huang, D. J. Chung, Y. C. Chang and C. J. Wang, J. Agric. Food Chem., 2013, 61, 6069–6076.
18 T. Wu, X. Qi, Y. Liu, J. Guo, R. Zhu, W. Chen, X. Zheng and T. Yu, Food Chem., 2013, 141, 482–487.
19 J. Zheng, C. Ding, L. Wang, G. Li, J. Shi, H. Li, H. Wang and Y. Suo, Food Chem., 2011, 126, 859–865.
20 Y. Duan, F. Chen, X. Yao, J. Zhu, C. Wang, J. Zhang and X. Li, Int. J. Environ. Res. Public Health, 2015, 12, 8332–8347.
21 T. Wu, Q. Tang, Z. Gao, Z. Yu, H. Song, X. Zheng and W. Chen, PLoS One, 2013, 8, e77585.
22 L. Folch, M. Lees and G. H. Sloane Stanley, J. Biol. Chem., 1957, 226, 497–509.
23 E. H. Ahrens Jr, W. Insull Jr, J. Hirsch, W. Staffel, M. L. Peterson, J. W. Farquhar, T. Miller and H. J. Thomasson, Lancet, 1959, 1, 115–119.
24 H. Pan, Y. Gao and Y. Tu, Molecules, 2016, 21, 1659.
25 K. Thompson, W. Pederick and A. B. Santhakumar, Food Funct., 2016, 7, 2169–2178.
26 J. Overall, S. A. Bonney, M. Wilson, A. Beermann, M. H. Grace, D. Esposito, M. A. Lila and S. Komarnytsky, Int. J. Mol. Sci., 2017, 18, 422.
27 D. Li, P. Wang, Y. Luo, M. Zhao and F. Chen, Crit. Rev. Food Sci. Nutr., 2017, 57, 1729–1741.
28 V. E. Atabay, M. Lutfioglu, B. Avci, E. E. Sakallioglu and A. Aydogdu, J. Periodontal Res., 2017, 52, 51–60.
29 A. Cassidy, G. Rogers, J. J. Peterson, J. T. Dwyer, H. Lin and P. F. Jacques, Am. J. Clin. Nutr., 2015, 102, 172–181.
30 B. Youssf, K. Gul, A. A. Wani and P. Singh, Crit. Rev. Food Sci. Nutr., 2016, 56, 2223–2230.
31 Q. Ma, Y. Guo, L. Sun and Y. Zhuang, Nutrients, 2017, 9, 801.
32 M. White, *Obes. Rev.*, 2007, 8(suppl. 1), 99–107.
33 D. Zhang, J. Christianson, Z. X. Liu, L. Tian, C. S. Choi, S. Neschen, J. Dong, P. A. Wood and G. I. Shulman, *Cell Metab.*, 2010, 11, 402–411.
34 T. Wu, Z. Yu, Q. Tang, H. Song, Z. Gao, W. Chen and X. Zheng, *Food Funct.*, 2013, 4, 1654–1661.
35 A. Fernandez-Sanchez, E. Madrigal-Santillan, M. Bautista, J. Esquivel-Soto, A. Morales-Gonzalez, C. Esquivel-Chirino, I. Durante-Montiel, G. Sanchez-Rivera, C. Valadez-Vega and J. A. Morales-Gonzalez, *Int. J. Mol. Sci.*, 2011, 12, 3117–3132.
36 I. Savini, V. Gasperi and M. V. Catani, in *Obesity*, Springer, 2016, pp. 65–86.
37 S. Khurana, M. Piche, A. Hollingsworth, K. Venkataraman and T. C. Tai, *Can. J. Physiol. Pharmacol.*, 2013, 91, 198–212.
38 A. Zdarilova, A. Rajnochova Svobodova, K. Chytilova, V. Simanek and J. Ulrichova, *Food Chem. Toxicol.*, 2010, 48, 1555–1561.
39 E. J. Park, J. H. Lee, G. Y. Yu, G. He, S. R. Ali, R. G. Holzer, C. H. Osterreicher, H. Takahashi and M. Karin, *Cell*, 2010, 140, 197–208.
40 T. Deng, C. J. Lyon, S. Bergin, M. A. Caligiuri and W. A. Hsueh, *Annu. Rev. Phytopathol.*, 2016, 11, 421–449.
41 Y. Yu, Y. Wu, A. Szabo, Z. Wu, H. Wang, D. Li and X. F. Huang, *Endocrinology*, 2013, 154, 3130–3140.
42 R. J. Thoppil, D. Bhatia, K. F. Barnes, E. Haznagy-Radnai, J. Hohmann, A. S. Darvesh and A. Bishayee, *Curr. Cancer Drug Targets*, 2012, 12, 1244–1257.
43 S. G. Lee, B. Kim, Y. Yang, T. X. Pham, Y.-K. Park, J. Manatou, S. I. Koo, O. K. Chun and J.-Y. Lee, *J. Nutr. Biochem.*, 2014, 25, 404–411.
44 D. Esposito, T. Damsud, M. Wilson, M. H. Grace, R. Strauch, X. Li, M. A. Lila and S. Komarnytsky, *J. Agric. Food Chem.*, 2015, 63, 6172–6180.
45 G. Jamar, D. Estadella and L. P. Pisani, *BioFactors*, 2017, 43, 507–516.
46 C. A. Morais, V. V. de Rosso, D. Estadella and L. P. Pisani, *J. Nutr. Biochem.*, 2016, 33, 1–7.